Swiggy Reports ₹625.5 Cr Net Loss in Q2 Despite Revenue Growth
Mankind Pharma Q2 Net Profit Surges 29%, Beats Forecasts
Last Updated: 5th November 2024 - 05:38 pm
Mankind Pharma Ltd. reported a 29% increase in consolidated net profit for the second quarter of fiscal 2025, surpassing analysts' expectations. The company recorded a net profit of ₹658.88 crore for the quarter ending September 30, 2024, up from ₹473 crore in the same period last year, as per a filing on Tuesday. Bloomberg-tracked analysts had projected a profit of ₹600 crore.
Mankind Pharma Q2 Results Highlights
- Revenue: Up 13.6% to ₹3,076.51 crore versus ₹2,708.10 crore.
- Net Profit: Up 29% to ₹658.88 crore versus ₹511.18 crore.
- EBITDA: Up 25% to ₹850.04 crore versus ₹682.65 crore. Margin at 27.6% versus 25.2%.
- Market Reaction: Shares closed 0.62% lower on Tuesday, as against a 0.91% advance in the benchmark Nifty 50.
iInvest in Indian Markets and Unlock Future Potential With 5paisa!
Stock Market Reaction
Mankind Pharma stock price closed 0.62% lower on Tuesday, as against a 0.91% advance in the benchmark Nifty 50.
About Mankind Pharma
Mankind Pharma Limited is a pharmaceutical company that specializes in the development, production, and marketing of a wide array of pharmaceutical formulations. These formulations address both acute and chronic therapeutic needs. Additionally, the company offers a variety of consumer healthcare products and primarily serves the Indian market.
- Flat ₹20 Brokerage
- Next-gen Trading
- Advance Charting
- Actionable Ideas
Trending on 5paisa
03
5paisa Research Team
Corporate Actions Related Articles
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.